【摘要】 目的　观察干扰素α2 b和病毒唑联合疗法与单用干扰素α2 b治疗慢性丙型肝炎的生化、病毒学应答以及使用安全性评估。方法　慢性丙型肝炎患者 5 0例 ,随机双盲分为干扰素α2 b(3MU,每周 3次 )和病毒唑 (1 0 5 0 m g/ d)联合治疗组与单用干扰素α2 b治疗组。疗程 2 4周 ,停药后再随访 2 4周 ,在治疗 2 4周、随访 2 4周时不能测得 HCV RNA为病毒学立即和持续应答。结果　治疗结束时联合治疗组 2 3例 (76 .6 7% )达到病毒学应答 ,而对照组仅 9例 (45 .0 0 % ,P<0 .0 5 )。在随访期联合治疗组病毒学持续应答率也较对照组高 (P<0 .0 5 )。联合疗法也可用于以往曾单用干扰素无效的病人 ,并取得较好的疗效。结论　干扰素α2 b和病毒唑联合治疗慢性丙型肝炎较单用干扰素α2 b具有较高的病毒学应答。更多还原

【Abstract】 Objective To investigate the biochemical and virological response and safety of treatment with interferon α 2b and ribavirin compared with interferon α 2b alone. Methods In this double blind trial 50 patients were randomly assigned to treatment with interferon α 2b (3 MU three times a week) in combination with ribavirin (1 050 mg per day) or interferon α 2b alone for 24 weeks and then followed for a further 24 weeks. The primary endpoint was the sustained virological response defined as no detectable HCV RNA by PCR at both week 24 and week 48. Results Twenty three (76.67%) of the 30 patients in the interferon α 2b and ribavirin group had a virological response compared with nine (45.00%) of the 20 patients in the interferon α 2b alone group (\%P\%<0.05). At the follow up, the proportion of patients with a virological response was greater in the interferon α 2b and ribavirin group than the interferon α 2b alone group (\%P\%<0.05). Combined therapy may be better for chronic hepatitis C in patients with a previous non response to interferon alone. Conclusion Most of the patients with chronic hepatitis C have a sustained virological response with combine interferon α 2b and ribavirin therapy. The combine therapy is better than the only interferon α 2b treatment.更多还原